Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Advanced Search

Search

You could also try: testing (1000), conducting tests (149)

Panitumumab (14 day) Ver 1.2

Description: Chemotherapy Protocol COLORECTAL CANCER PANITUMUMAB (14 day) This regimen may require funding Regimen Colorectal Cancer – Panitumumab (14 day) Indication Metastatic colorectal
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Colorectal/Panitumumab14dayVer12.pdf

Irinotecan Ver 1.2

Description: Chemotherapy Protocol COLORECTAL CANCER Regimen IRINOTECAN Colorectal Cancer– Irinotecan Indication Second line treatment of advanced colorectal cancer WHO performance status 0
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Colorectal/IrinotecanVer12.pdf

Capecitabine-Radiotherapy

Description: Chemotherapy Protocol PANCREATIC CANCER CAPECITABINE (RADIOTHERAPY) Regimen • Pancreatic Cancer – Capecitabine (Radiotherapy) Indication • Locally advanced, non-metastatic pancreatic cancer • WHO performance status
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Pancreas/Capecitabine-Radiotherapy.pdf

Neuroendocrine-Sunitinib Ver 1

Description: Chemotherapy Protocol NEUROENDOCRINE SUNITINIB Regimen Neuroendocrine - Sunitinib Indication The 1st, 2nd or 3rd line treatment of pancreatic neuroendocrine carcinomas that are
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Endocrinecancer/Neuroendocrine-Sunitinib-Ver-1.pdf

Opt out of research

Description: Auto Generated Title While most of our research is done on an opt in basis, participants also have the opportunity to
Url: /ClinicalResearchinSouthampton/Public-and-patients/Opt-out-of-research.aspx

Key research funders_remit_Nov2019

Description: Key research funders – their focus and philosophies UKRI – UK Research and Innovation Launched in April 2018 and with a £7bn budget
Url: /Media/Southampton-Clinical-Research/Grants/Download/Key-research-funders-remit-Nov2019.pdf

Laboratory medicine user handbook rev 22

Description: University Hospital Southampton NHS Foundation Trust LABORATORY MEDICINE G3.7 Laboratory Medicine user handbook rev 22 G3.7 Laboratory Medicine Laboratory
Url: /Media/UHS-website-2019/Docs/Services/Pathology/Lab-med/Laboratory-medicine-user-handbook.pdf

Ibrutinib-Venetoclax

Description: Chemotherapy Protocol Chronic Lymphocytic Leukaemia IBRUTINIB-VENETOCLAX Regimen CLL – Ibrutinib & Venetoclax Indication • Ibrutinib plus Venetoclax is recommended as an option for
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/Ibrutinib-Venetoclax-Ver1.1.pdf

B-AVD (Brentuximab vedotin-Dacarbazine-Doxorubicin-Vinblastine)

Description: Chemotherapy Protocol LYMPHOMA BRENTUXIMAB VEDOTIN-DACARBAZINE-DOXORUBICIN-VINBLASTINE (B- AVD) Regimen • Lymphoma – Brentuximab vedotin - Dacarbazine-Doxorubicin-Vinblastine Indication • Previously untreated stage
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/B-AVD-Brentuximab-vedotin-Dacarbazine-Doxorubicin-Vinblastine.pdf

Lymphoma patient-initiated follow-up - patient information

Description: This booklet explains what patient-initiated follow-up (PIFU) for lymphoma is and what it involves so you know what to
Url: /Media/UHS-website-2019/Patientinformation/Cancercare/Lymphoma-patient-initiated-follow-up-475-PIL.pdf

361 to 370 of 517

Previous … 35 36 37 38 39 … Next